Details

Autor(en) / Beteiligte

• Hjorth-Hansen, H
• Stentoft, J
• Richter, J
• Koskenvesa, P
• Hoglund, M
• Dreimane, A
• Porkka, K
• Gedde-Dahl, T
• Gjertsen, B T
• Gruber, F X
• Stenke, L
• Eriksson, K M
• Markevaern, B
• Luebking, A
• Vestergaard, H
• Udby, L
• Bjerrum, O W
• Persson, I
• Mustjoki, S
• Olsson-Stromberg, U

Titel

Safety and efficacy of the combination of pegylated interferon- alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Ist Teil von

• Leukemia, 2016-09, Vol.30 (9), p.1853-1860

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Dasatinib (DAS) and interferon- alpha have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon- alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR super(4) was achieved by 46% and MR super(4.5) by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS plus or minus PegIFN is warranted.